TPST Tempest Therapeutics, Inc. Common Stock

XNAS 10.14 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TPST $10.14 —
Key stats
$10.14
Pre-market $0.54 +6.33%
52-Week Range
$0.50 – $5.57
YTD
+587.46%
Straddle Price
$1.55
P/C Vol Ratio
0.83
Market Cap
$0.0B
Open
$0.51
Day Range
$0.50 – $0.52
Volume
66,149
Prev Close
$0.51
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.69
Cost of Equity (CAPM)12.97% (VRP-adj)
WACC13.08%
Volatility Risk Premium-202.7pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)3713.0%
Book / Price27.6%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$0.86 (Market Anchor value)
SMA 20 / Bollinger Mid$0.69
Bollinger Width / SMA209635.6% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABBV, ABT, AZN, JNJ, LLY, MRK, NVO, NVS
Blended Fair Value
$1.15
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 42.5× · 7 peers
Peer EV/EBITDA n/a 0% median 23.6× · 7 peers
Peer P/B $1.15 100% median 8.2× · 6 peers
Peer P/S n/a 0% median 6.4× · 7 peers
Market Anchor (SMA50) $0.86 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
4
List Date
2021-06-28
CIK
0001544227
Next Earnings
2026-11-04 (After-Close)
EPS Forecast
($0.32) (1 est.)
Headquarters
Brisbane, CA
Homepage
https://www.tempesttx.com

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---27.16%62.42%-14.06%6.59%84.41%22.44%
Feb---17.05%-6.88%-8.85%-11.93%-7.69%-10.48%
Mar--3.68%42.33%6.25%-5.70%-26.13%4.09%
Apr--12.81%-6.61%-36.21%-23.46%22.84%-6.13%
May---25.00%-30.45%-8.29%-13.14%-25.00%-20.38%
Jun-16.32%-23.76%-11.81%-32.62%1.49%-23.45%-17.75%
Jul35.68%-11.35%-30.22%-16.82%4.78%-22.86%-6.80%
Aug-1.64%2.86%-41.52%-24.56%32.44%24.56%-1.31%
Sep0.49%-17.54%-43.56%18.64%1.08%-20.54%-10.24%
Oct-22.38%0.00%1231.17%-31.19%0.30%-36.71%*190.20%
Nov-15.60%-18.04%-5.00%4.46%-68.06%---20.45%
Dec-43.47%-24.84%28.28%-12.28%-5.90%---11.64%
Total-58.44%-81.28%360.72%-84.60%-74.74%-57.15%0.75%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.69
SMA 50: $0.86
SMA 200: $1.45
Current: $0.51
EMA 12: $0.60
EMA 26: $0.70
MACD: -0.1001 | Signal: -0.0139
BEARISH
ADX (14): 18.73
RANGE
+DI: 15.34
−DI: 27.02

Momentum Oscillators

RSI (14): 28.04
OVERSOLD
Stoch %K: 2.42
Stoch %D: 2.17
Williams %R: -96.96

Volume & Volatility

BB Upper: $0.91
BB Lower: $0.46
NEUTRAL
OBV: 77,478,412
Vol SMA 20: 279,207
Vol ROC: -59.58%
ATR: $0.07
True Range: $0.02
HV 20: 47.3%
HV 30: 202.7%
HV 60: 158.0%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall assessment: BEARISH with confidence level (4/10) Key drivers and primary risks: * Bearish momentum from MACD * Oversold RSI and Stochastic signals * High volatility and potential for a sharp decline Recent news sentiment impact: * Positive headlines may not be enough to overcome bearish momentum

Technical Analysis Trend Direction: Short-term (1-4 weeks): Downtrend, Medium-term (1-3 months): Sideways, Long-term (3-12 months): Uptrend Support/Resistance Levels: * Upper Bollinger Band: $2.18 * Middle line: $1.89 * Lower Bollinger Band: $1.60 Momentum Signals: * RSI: 35.97 (neutral) * MACD: -0.06 / Signal: -0.03 / Histogram: -0.03 (bearish) * Bollinger Bands: Oversold Volume Analysis: * Volume SMA 20: 122394.60 * OBV: -273416.13

News & Sentiment Analysis Recent Headlines Summary: Positive news headlines from clinical updates and partnerships, but may not be enough to overcome bearish momentum Sentiment Assessment: Neutral (4 positive headlines out of 6) Catalyst Identification: * Upcoming clinical update at ISCT 2026 Annual Meeting * Planned U.S. registrational study in 2026 Market Narrative: Positive news headlines may not be enough to overcome bearish momentum and high volatility

Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta >1.5) Volatility Regime: Current vs historical volatility levels: * Historical Volatility: HV20 91.0% / HV30 98.2% / HV60 109.4% Options Market Signals: * IV Rank: 0.0% (Low - shows if volatility is historically high/low) * Current IV: 0.0% * Expected Move: $1.55 (0 DTE), 7-DTE: $1.55 Downside Protection: * Support levels: Lower Bollinger Band ($1.60) and historical low prices

Market Context & Positioning Sector Performance: Relative strength vs sector/market: Neutral Institutional Activity: Volume patterns suggesting institutional interest: None Correlation Analysis: How stock moves relative to market (R-squared interpretation): High correlation with the market, but higher volatility than the S&P 500 Relative Valuation: Position within trading range: Below average price and below the middle line of the Bollinger Bands

Key Levels & Action Items Critical Price Levels: * Lower Bollinger Band ($1.60) * Historical low prices Breakout/Breakdown Levels: * Upper Bollinger Band ($2.18) - potential upside target Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches Risk Management: Stop-loss levels and position sizing considerations

Additional Comments

Please note that the analysis is based on the provided data, and further research may be necessary to fully understand the stock's dynamics. The high volatility and bearish momentum indicate a higher risk for the stock. Investors should consider their risk tolerance and overall market conditions before making any investment decisions.

Generated
News
All TPST news →
Earnings History
8 of 8 under expected move
Avg Expected Move
80.23%
Avg Actual Move
8.38%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-11-08 After-Close 32.40% 16.31% 0.50x Within
2024-03-19 After-Close 56.80% 0.53% 0.01x Within
2024-05-09 After-Close 30.73% 6.34% 0.21x Within
2024-08-08 After-Close 99.31% 14.18% 0.14x Within
2024-11-12 After-Close 254.85% 10.50% 0.04x Within
2025-03-27 After-Close 62.50% 8.07% 0.13x Within
2025-05-13 Pre-Market 64.05% 1.16% 0.02x Within
2025-08-11 After-Close 41.20% 9.99% 0.24x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TPST Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $1.55
7-DTE Move: $1.55
Days to Exp: — (2025-10-17)

Options Flow

Call Volume: 133
Put Volume: 110
P/C Volume: 0.827
NEUTRAL
Call OI: 1,255
Put OI: 259
P/C OI: 0.206
Total OI: 1,514

ATM Options Pricing

ATM Call: $0.38
ATM Put: $1.18
Call %: 3.7%
Put %: 11.6%

Chain Summary

Chain Volume: 243
Chain OI: 1,514
Last Updated: 10/17/2025
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 13 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 13 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.55Oct 17
Beta Analysis

Risk Metrics

Beta: 0.3504
Alpha: -130.57%
Correlation: 0.0283
R-Squared: 0.1%
Stock Volatility: 157.6%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TPST
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$22K
0.00%
#6160 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TPST Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 5,831,098 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

23 filers1,457,997 shares$1.91M value25.00% of float
# Filer Shares Value % of Total % of Float Period
1 SABBY MANAGEMENT, LLC 511,286 $567.53K 29.77% 8.77% 2026-06-30
2 Vanguard Group Inc Custodian 162,560 $466.55K 24.47% 2.79% 2025-12-31
3 Versant Venture Management, LLC 269,772 $299.45K 15.71% 4.63% 2026-06-30
4 Vanguard Capital Management LLC 233,888 $259.62K 13.62% 4.01% 2026-06-30
5 Geode Capital Management, LLC Custodian 86,625 $96.16K 5.04% 1.49% 2026-06-30
6 Vanguard Fiduciary Trust Co 68,908 $76.49K 4.01% 1.18% 2026-06-30
7 BlackRock, Inc. Custodian 39,068 $43.37K 2.27% 0.67% 2026-06-30
8 Squarepoint Ops LLC 30,900 $34.30K 1.80% 0.53% 2026-06-30
9 Northern Trust Corp Custodian 20,136 $22.35K 1.17% 0.35% 2026-06-30
10 Citadel Advisors LLC Custodian 19,820 $22.00K 1.15% 0.34% 2026-06-30
11 UBS Group AG Custodian 5,636 $6.25K 0.33% 0.10% 2026-06-30
12 Tower Research Capital LLC (TRC) Custodian 3,922 $4.35K 0.23% 0.07% 2026-06-30
13 CIBC Private Wealth Group LLC 1,080 $3.10K 0.16% 0.02% 2025-12-31
14 Morgan Stanley Custodian 2,022 $2.24K 0.12% 0.03% 2026-06-30
15 OSAIC HOLDINGS, INC. Custodian 1,513 $1.67K 0.09% 0.03% 2026-06-30
16 Federation des caisses Desjardins du Quebec Custodian 292 $324 0.02% <0.01% 2026-06-30
17 Jones Financial Companies LLLP Custodian 239 $258 0.01% <0.01% 2026-06-30
18 Barclays PLC Custodian 222 $246 0.01% <0.01% 2026-06-30
19 SBI Securities Co., Ltd. 56 $47 <0.01% <0.01% 2026-09-30
20 Parallel Advisors, LLC 18 $20 <0.01% <0.01% 2026-06-30
21 BNP Paribas Financial Markets Custodian 3 $3 <0.01% <0.01% 2026-06-30
22 Caitong International Asset Management Co., Ltd 3 $3 <0.01% <0.01% 2026-06-30
23 Royal Bank of Canada Custodian 28 $0 0.00% <0.01% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

TPST Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 Nancy Freda Smith Director Grant (A) +25,000 opt — EDGAR
2026-06-23 Matthew Angel CEO and President Buy (P) +231,482 $2.16 $500.0K EDGAR
2026-06-17 John D. Yee Director Grant (A) +25,000 opt — EDGAR
2026-06-08 William Drake Richey Director Grant (A) +25,000 opt — EDGAR
2026-04-02 Nicholas Maestas Chief Financial Officer Grant (A) +140,000 opt — EDGAR
2026-04-02 Justin Trojanowski Corporate Controller Grant (A) +22,000 opt — EDGAR
2026-03-25 Matthew Angel CEO and President Buy (P) +231,482 $2.16 $500.0K EDGAR
2026-02-06 Matthew Angel CEO and President Grant (A) +269,621 opt — EDGAR
2026-01-28 Michael Raab Director Grant (A) +1,230 opt — EDGAR
2026-01-28 Ronit Simantov Director Grant (A) +1,230 opt — EDGAR
2026-01-28 Geoffrey Nichol Director Grant (A) +1,230 opt — EDGAR
2026-01-28 Christine A Pellizzari Director Grant (A) +1,230 opt — EDGAR
2025-01-06 Stephen R Brady President and CEO Grant (A) +550,000 opt — EDGAR
2025-01-06 Samuel Whiting Chief Medical Officer Grant (A) +270,000 opt — EDGAR
2025-01-06 Justin Trojanowski Corporate Controller Grant (A) +30,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TPST Insider Holdings

4 insiders · @ $0.51
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Matthew Angel CEO and President 5,068,552 $2.59M $1.00M 3 2026-06-23
2 Stephen R Brady President and CEO 3,567 $1.8K $73.8K 8 2025-01-06
3 Justin Trojanowski Corporate Controller 1,705 $870 $16.2K 7 2026-04-02
4 Samuel Whiting Chief Medical Officer 736 $376 $18.1K 9 2025-01-06
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TPST Board & Officers

As of SEC filings through Oct 2, 2026

Directors 7

Officers 2

10% owners 1

Changes in the last 10 years (84)
Sep 22, 2026Nancy Freda Smith became a director
Jun 4, 2026William Drake Richey became a director
Jun 4, 2026John D. Yee became a director
May 29, 2026The company announced the departure of Nicholas Maestas as Chief Financial Officer in an SEC filing
Feb 3, 2026The company announced the departure of Stephen R Brady as President and CEO in an SEC filing
Feb 3, 2026Matthew Angel became a director
Feb 3, 2026Matthew Angel became a 10% owner
Feb 3, 2026Matthew Angel became CEO and President
Nov 19, 2025The company announced the departure of Geoffrey Nichol from the board in an SEC filing
Jan 6, 2025Nicholas Maestas listed as Chief Financial Officer (previously VP of Strategy and Finance) in SEC filings
Oct 13, 2023Stephen R Brady listed as President and CEO (previously Chief Executive Officer) in SEC filings
Sep 2, 2023The company announced the departure of Thomas W. Dubensky from the board in an SEC filing
Sep 2, 2023The company announced the departure of Thomas W. Dubensky as President in an SEC filing
Sep 30, 2022Justin Trojanowski became Corporate Controller
Sep 19, 2022The company announced the departure of Pierre Lorenzo as Corporate Controller in an SEC filing
Apr 29, 2022Versant Vantage II, L.P. became a 10% owner
Apr 29, 2022Versant Vantage II GP-GP, LLC became a 10% owner
Apr 29, 2022Versant Vantage II GP, L.P. became a 10% owner
Dec 30, 2021Rock Springs Capital Master Fund LP became a 10% owner
Dec 30, 2021Rock Springs Capital Management LP became a 10% owner
Not reported recently (50)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TPST Proposed Insider Sales (Form 144)

Latest: 2024-08-13
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-08-13 Versant Venture Capital VI, L.P. Owner 387,999 $427.0K 2024-08-12 Jones Trading Institutional Serv… — EDGAR
2024-08-09 Versant Venture Capital VI, L.P. 10% Stockholder 400,000 — 2024-08-08 BTIG, LLC — EDGAR
2023-11-02 Dubensky Thomas W. Officer, Director 30,000 $131.5K 2023-10-25 Merrill Lynch — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
2 ETFs hold TPST
2 shown · $195.13K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $107,578 — 2026-09-30
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $87,555 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-6.01
TTM Revenue
—
TTM Net Income
$-43.10M
TTM Op. Cash Flow
$-26.38M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-27.70M$-2.53$-7.60M
Q4 '252025-12-31—$-4.02M$-0.62$-3.57M
Q3 '252025-09-30—$-3.51M$-0.79$-6.78M
Q2 '252025-06-30—$-7.87M$-2.07$-8.43M
Q1 '252025-03-31—$-10.86M$-3.16$-8.04M
Q4 '242024-12-31—$-13.81M$-4.02$-10.15M
Q3 '242024-09-30—$-10.56M$-5.32$-10.18M
Q2 '242024-06-30—$-9.57M$-5.52$-5.51M
Q1 '242024-03-31—$-7.90M$-4.62$-7.19M
Q4 '232023-12-31—$-7.49M$-4.42$-6.17M
Q3 '232023-09-30—$-6.79M$-6.24$-6.49M
Q2 '232023-06-30—$-7.58M$-7.02$-6.39M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.62
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-5243.1%
ROA
-401.0%
Div Yield
0.00%
FCF Yield
-886.78%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.98M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
608.43K
SI % of Float
6.02%
Days to Cover
1.00
Short Vol Ratio
40.2%
Free Float
10.11M
Float %
63.3%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14